Literature DB >> 2229063

Serum transferrin receptor is a truncated form of tissue receptor.

Y J Shih1, R D Baynes, B G Hudson, C H Flowers, B S Skikne, J D Cook.   

Abstract

Recent studies have provided immunological evidence for the existence of transferrin receptor in human serum and have revealed that its concentration is a sensitive measure of erythropoiesis and iron deficiency. The present study was undertaken to establish the molecular identity of this immunoreactive component. Purification from human serum was accomplished by immunoaffinity chromatography using, as the ligand, monoclonal antitransferrin receptor antibody. The receptor preparation contained two major components with Mr of 75,000 and 85,000, which were identified as transferrin and transferrin receptor, respectively. The physicochemical and immunochemical properties of the 85,000 serum receptor were compared with those established for intact placental transferrin receptor. The serum receptor exhibited an apparent Mr = 85,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis under non-reducing conditions, as compared with 190,000 for placental transferrin receptor. Upon reduction, the Mr of serum receptor was unaltered, whereas, the 190,000 placental receptor dimer decreased to the expected monomer value of 95,000. Amino-terminal amino acid sequence analysis revealed that residues 1-19 of serum receptor were identical to residues 101-119 of intact receptor. These findings provide physicochemical evidence for the existence of transferrin receptor in human serum, establish its molecular identity as a truncated form lacking the cytoplasmic and transmembrane domains (residues 1-100) of intact receptor, and demonstrate that it exists as a transferrin-receptor complex in serum.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2229063

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  Cord blood transferrin receptors to assess fetal iron status.

Authors:  D G Sweet; G A Savage; R Tubman; T R Lappin; H L Halliday
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-07       Impact factor: 5.747

Review 2.  Cytokines, receptors, and inhibitors.

Authors:  G Gehr; T Braun; W Lesslauer
Journal:  Clin Investig       Date:  1992-01

3.  C-terminal truncated forms of Met, the hepatocyte growth factor receptor.

Authors:  M Prat; T Crepaldi; L Gandino; S Giordano; P Longati; P Comoglio
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

4.  The importance of serum transferrin receptor level in the diagnosis of functional iron deficiency due to recombinant human erythropoietin treatment in haemodialysis patients.

Authors:  H Z Tonbul; H Kaya; N Y Selçuk; S B Tekin; A San; F Akçay; E Akarsu
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

Review 5.  Transferrin receptor in tissue and serum: updated clinical significance of soluble receptor.

Authors:  Yutaka Kohgo; Yoshihiro Torimoto; Junji Kato
Journal:  Int J Hematol       Date:  2002-10       Impact factor: 2.490

Review 6.  Case studies: iron.

Authors:  Sean Lynch
Journal:  Am J Clin Nutr       Date:  2011-07-06       Impact factor: 7.045

Review 7.  The relevance of the intestinal crypt and enterocyte in regulating iron absorption.

Authors:  Phillip S Oates
Journal:  Pflugers Arch       Date:  2007-05-01       Impact factor: 3.657

8.  Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10.

Authors:  Cristina I Caescu; Grace R Jeschke; Benjamin E Turk
Journal:  Biochem J       Date:  2009-10-23       Impact factor: 3.857

9.  A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

Authors:  N Pedersen; M Schmitt; E Rønne; M I Nicoletti; G Høyer-Hansen; M Conese; R Giavazzi; K Dano; W Kuhn; F Jänicke
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

10.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.